Gabapentin Solution
Product Images NDC 72888-104

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 72888-104). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Advagen Pharma Ltd, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Equation (Gabapentin Oral Solution Figure 01)

Equation (Gabapentin Oral Solution Figure 01)
An illustration showing the formula for calculating Creatinine Clearance (CLCr), including variables such as age in years, weight in kilograms, serum creatinine in mg/dL, and a correction factor for female patients.*
FDA Label Image

Figure 1 (Gabapentin Oral Solution Figure 02)

Figure 1 (Gabapentin Oral Solution Figure 02)
A line graph depicting mean pain scores over eight weeks during a 4-week dose titration period followed by a 4-week fixed dose period. It compares placebo and gabapentin 3600 mg/day, showing a downward trend in pain score for gabapentin, while the placebo remains relatively stable.*
FDA Label Image

Figure 2 (Gabapentin Oral Solution Figure 03)

Figure 2 (Gabapentin Oral Solution Figure 03)
Line graph depicting mean pain scores over a 7-week period for Placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day groups. The timeline includes a 3-week dose titration period followed by a 4-week fixed dose period. Gabapentin groups show a decrease in mean pain score compared to placebo.*
FDA Label Image

Figure 3 (Gabapentin Oral Solution Figure 04)

Figure 3 (Gabapentin Oral Solution Figure 04)
A bar chart comparing results from two studies. Study 1 shows percentages for PBO (12%) and GBP 3600 (29%), with significance markers indicating p < 0.01. Study 2 shows percentages for PBO (14%), GBP 1800 (32%), and GBP 2400 (34%), with significance markers indicating p < 0.001. The y-axis is labeled as a percentage from 0 to 100%, and bars represent treatment groups.*
FDA Label Image

Figure 4 (Gabapentin Oral Solution Figure 05)

Figure 4 (Gabapentin Oral Solution Figure 05)
A scatter plot graph depicting percentage difference on the Y-axis against daily dose in mg on the X-axis. It compares data points from three studies (labeled as Study a, Study b, and Study c) for daily doses ranging from 600 mg to 1800 mg.*
FDA Label Image

Gabapentin Oral Solution (NDC 72888-104-25)

Gabapentin Oral Solution (NDC 72888-104-25)
Label for Gabapentin Oral Solution 250 mg per 5 mL by Advagen Pharma Ltd. The label indicates the oral solution dosage form, 470 mL bottle size, and prescription-only status. Storage instructions specify refrigeration at 2°C to 8°C. The label includes the NDC 72888-104-25 and distributor contact information in Plainsboro, NJ, USA.*
FDA Label Image

Chemical Structure (Gabapentin Oral Solution Structure)

Chemical Structure (Gabapentin Oral Solution Structure)
Chemical structure of gabapentin, depicting a cyclohexane ring attached to amino (CH2NH2) and carboxymethyl (CH2CO2H) groups, corresponding to the active ingredient in Gabapentin 250 mg/5 mL oral solution by Advagen Pharma Ltd.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.